Other News

Bay Area’s HeartFlow Scores $240M

HeartFlow Completes Series E Financing, Securing $240 Million Proceeds Will Support Commercialization of HeartFlow® FFRct Analysis, Continued Technology Innovation and Additional Clinical Studies REDWOOD CITY, Calif.–(BUSINESS WIRE)– HeartFlow. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial […]

LivaNova Takes Out TandemLife in $250M Deal

LivaNova to Acquire TandemLife Company will add advanced cardiopulmonary temporary support solutions to its portfolio LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire TandemLife, a privately held company focused on advanced cardiopulmonary temporary support solutions (“TandemLife”). The […]

McDermott & Bull Adds Principal Consultant in Denver with the Acquisition of Prime-Core Executive Search

IRVINE, California and DENVER, Colorado, February 13, 2018 – McDermott & Bull announced today the acquisition of Denver-based Prime-Core Executive Search and the addition of Ken Dropiewski as Principal Consultant.  Dropiewski will join the firm’s Life Sciences Group, specializing in the Med-Tech space. “The addition of Ken to our firm is a huge […]

Cardiovascular Systems, Inc. Announces First Patients Treated from Radial Access Using Its Diamondback 360 Extended Length Peripheral Orbital Atherectomy Device

Feb. 14, 2018 12:00 UTC Device provides alternative access point to treat patients suffering from peripheral artery disease ST. PAUL, Minn.–(BUSINESS WIRE)– Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, announced today that the first patients were […]

Claret Medical’s Sentinel Cerebral Protection System Emerging as U.S. Standard of Care for Protecting the Brain from Risk of Stroke During Transcatheter Aortic Heart Valve Replacement

Feb. 14, 2018 13:00 UTC 50 Premier U.S. Centers Adopt Sentinel Device in First Phase of Commercial Launch More Than 5,500 Patients Protected Worldwide Only Commercially Available TAVR Cerebral Protection Device in U.S., Europe and Asia Stacy Enxing Seng Joins Company’s Board of Directors SANTA ROSA, Calif.–(BUSINESS WIRE)– Since FDA […]

FDA Permits Marketing of Clinical Decision Support Software for Alerting Providers of a Potential Stroke in Patients

SILVER SPRING, Md., Feb. 13, 2018 /PRNewswire-USNewswire/ — Today, the U.S. Food and Drug Administration permitted marketing of the Viz.AI Contact application, a type of clinical decision support software designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients. A stroke is […]

Avinger Announces Pricing of $18M Underwritten Public Offering

Secured Lenders Convert $38 Million of Debt into Equity REDWOOD CITY, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) — Avinger, Inc.(NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the pricing of an underwritten public offering of Series B convertible preferred stock, together with warrants, for gross […]

Abiomed Wins Approval for Expanded FDA Indication for High Risk PCI Procedures

Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures DANVERS, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — Abiomed(Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the […]

Novoheart Signs Agreement with Sumocor to Develop Novel Therapeutics for Heart Failure

VANCOUVER, BRITISH COLUMBIA — (Marketwired) — Feb 14, 2018 — Novoheart(“Novoheart” or the “Company”) (TSX VENTURE: NVH), through its wholly owned US subsidiary, has entered into a commercial agreement with Sumocor LLC(“Sumocor”), a biotech company based in New York City that is focused on the development of therapeutics for cardiovascular diseases. Pursuant to […]

MyoKardia Begins Patient Dosing in Phase Ib Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients

Topline Results from First-in-Human Phase 1 Study of MYK-491 in Healthy Volunteers Demonstrated Tolerability and Increased Contractility SOUTH SAN FRANCISCO, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) —MyoKardia (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in […]